temozolomide

P3, N=300, Not yet recruiting, Gustave Roussy, Cancer Campus, Grand Paris

P1, N=42, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Jul 2032 --> Nov 2028 | Trial primary completion date: Dec 2026 --> Nov 2028

P1, N=40, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Sep 2026 | Trial primary completion date: May 2026 --> Sep 2026

These findings define a selenoprotein-driven malignant glioma state associated with immune evasion and therapeutic vulnerability. They further identify SELENOS as a potential therapeutic target and provide insight into how selenoprotein-related programs contribute to glioma progression.

Furthermore, the combination of miR-449b-5p, miR-329-3p, and miR-518c treatments with temozolomide led to synergistic enhancements in cell proliferation suppression and the induction of apoptosis and ferroptosis. More importantly, in vivo miR-329-3p treatment led to remarkable suppression of GBM tumor xenografts. These findings indicate that miR-329-3p-based tumor suppressor therapy may offer a multitargeted approach for GBM treatment.

We systematically evaluated the effects of six systemic agents commonly used in NEN therapy-isplatin, etoposide, 5-fluorouracil (5-FU), streptozotocin (STZ), temozolomide (TMZ), and everolimus-on SSTR2 and SSTR5 expression, as well as on uptake of 68Ga-DOTATOC, in BON-1 and QGP-1 cells, as well as the MS-18 cell line...In contrast, 5-FU, STZ, cisplatin, and everolimus showed heterogeneous, compound- and cell line-specific effects on SSTR2 expression and 68Ga-DOTATOC uptake, including both up- and downregulation depending on the model...Our findings highlight both the potential and the risks of systemic therapy-induced receptor modulation and therefore support further investigation of treatment sequencing strategies to optimize SSTR-targeted approaches. However, further studies are required to translate these observations to a clinical setting.

P2, N=225, Completed, University of Birmingham | Active, not recruiting --> Completed

The patient was subsequently referred for standard-of-care adjuvant chemoradiation, including external-beam radiation therapy with concurrent and adjuvant temozolomide, which represents the current recommended treatment approach for high-grade gliomas harboring H3K27M mutations...This unusual hemispheric H3K27M-mutant tumor morphologically mimicked an oligodendroglioma. We recommend routine H3K27M testing in IDH-wildtype hemispheric gliomas with ATRX loss.

The patients received tepotinib through ad hoc off-label requests, with a daily dosage of 450 mg after progression following radiotherapy-based first-line treatment, with or without temozolomide. These findings support the potential of tepotinib as a targeted therapy for MET-altered glioblastoma, consistent with preclinical evidence and previous case reports. Further research is warranted to better understand the efficacy and safety of MET inhibition in this patient population.

P1, N=20, Active, not recruiting, Valent Technologies, LLC | Recruiting --> Active, not recruiting

P1/2, N=90, Recruiting, St. Jude Children's Research Hospital | Trial primary completion date: Dec 2025 --> Dec 2026

P1, N=0, Withdrawn, SynerGene Therapeutics, Inc. | Not yet recruiting --> Withdrawn